
Apollomics Inc. — Investor Relations & Filings
Apollomics Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapies. The company's approach centers on creating treatments, particularly combination therapies, that can be integrated with other options to inhibit cancer. These therapies are designed to harness the body's immune system and target specific molecular pathways. Apollomics utilizes a science-driven methodology, including in-house research and development and rigorous clinical trials based on sound mechanistic rationale, with the goal of transforming the treatment landscape for patients with difficult-to-treat cancers.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K - Apollomics Inc. (0001944885) (Filer) | 2026-04-27 | English | |
| 20-F - Apollomics Inc. (0001944885) (Filer) | 2026-04-24 | English | |
| 6-K - Apollomics Inc. (0001944885) (Filer) | 2026-04-01 | English | |
| 3 - Apollomics Inc. (0001944885) (Issuer) | 2026-03-19 | English | |
| 3 - Apollomics Inc. (0001944885) (Issuer) | 2026-03-18 | English | |
| 3 - Apollomics Inc. (0001944885) (Issuer) | 2026-03-18 | English |
Browse filings by year
5 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
12 filings
| |||||
| 37437795 | 6-K - Apollomics Inc. (0001944885) (Filer) | 2026-04-27 | English | ||
| 36268432 | 20-F - Apollomics Inc. (0001944885) (Filer) | 2026-04-24 | English | ||
| 33150122 | 6-K - Apollomics Inc. (0001944885) (Filer) | 2026-04-01 | English | ||
| 32988495 | 3 - Apollomics Inc. (0001944885) (Issuer) | 2026-03-19 | English | ||
| 32980656 | 3 - Apollomics Inc. (0001944885) (Issuer) | 2026-03-18 | English | ||
| 32980631 | 3 - Apollomics Inc. (0001944885) (Issuer) | 2026-03-18 | English | ||
| 32980632 | 3 - Apollomics Inc. (0001944885) (Issuer) | 2026-03-18 | English | ||
| 32980627 | 3 - Apollomics Inc. (0001944885) (Issuer) | 2026-03-18 | English | ||
| 32980622 | 3 - Apollomics Inc. (0001944885) (Issuer) | 2026-03-18 | English | ||
| 32980526 | 3 - Apollomics Inc. (0001944885) (Issuer) | 2026-03-18 | English | ||
| 32980511 | 3 - Apollomics Inc. (0001944885) (Issuer) | 2026-03-18 | English | ||
| 32239067 | S-8 Filing | 2026-02-02 | English | ||
|
2025
3 filings
| |||||
| 13615298 | 6-K | 2025-12-22 | English | ||
| 13615294 | 6-K | 2025-12-12 | English | ||
| 13615293 | 6-K | 2025-11-19 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Amylyx Pharmaceuticals, Inc.
Develops therapies for neurodegenerative diseases and other…
|
AMLX | US | Manufacturing |
|
AN2 Therapeutics, Inc.
Biopharmaceutical firm developing boron-based drugs for inf…
|
ANTX | US | Manufacturing |
|
Ananda Pharma Plc
Biopharmaceutical firm developing cannabinoid-based medicin…
|
ANAN | GB | Manufacturing |
|
ANATOLİA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş.
Designs, develops, and manufactures molecular diagnostic so…
|
ANGEN | TR | Manufacturing |
|
ANAVEX LIFE SCIENCES CORP.
Clinical-stage biopharmaceutical company developing therape…
|
AVXL | US | Manufacturing |
|
Anbio Biotechnology
Develops and provides in-vitro diagnostic (IVD) solutions a…
|
NNNN | KY | Manufacturing |
|
Anebulo Pharmaceuticals, Inc.
Clinical-stage biotech developing therapies for acute canna…
|
ANEB | US | Manufacturing |
|
AnGes, Inc.
Biopharmaceutical firm developing gene-based and nucleotide…
|
4563 | JP | Manufacturing |
|
ANG Lifesciences India Limited
Develops and manufactures sterile dry powder and liquid inj…
|
540694 | IN | Manufacturing |
|
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.
Develops biopharmaceuticals, genetic engineering products, …
|
300009 | CN | Manufacturing |
Apollomics Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34696/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34696 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34696 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34696 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34696}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Apollomics Inc. (id: 34696)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.